Nationwide recall on these compound GLP-1 drugs

(NewsNation) — The FDA has issued a recall for 23 GLP-1 compounded vials from Apothecary Pharma LLC due to lack of assurance the vials are sterile.

The FDA has designated the recall as Class II, meaning exposure to the products could cause reversible or temporary health consequences and poses little risk of serious consequences from use, according to the FDA website.

What products to look out for:

The recall applies to 22 vials of Tirzepatide Injection, 18mg/mL, 4 mL Sterile Multi-Dose Vial, Rx only, Apothecary Pharma, LLC, 1913 Evans Road, Cary, NC 27513, NDC 85091-001-18. Tirzepatide is used in Zepbound and Mounjaro. Customers should look out for these specific codes:

Lot AP-202622, BUD 07-Oct-2026

Lot AP-202623, BUD 08-Oct-2026

Lot AP-202624, BUD 19-Oct-2026

Lot AP-202625, BUD 10/20/2026

Lot AP-202627, BUD 10/26/2026

Lot AP-202628, BUD 10/27/2026

Lot AP-202629, BUD 10/28/2026

Lot AP-202630, BUD 10/31/2026

Lot AP-202631, BUD 11/01/2026

Lot AP-202632, BUD 11/03/2026

Lot AP-202633, BUD 11/07/2026

Lot AP-202634, BUD 11/08/2026

Lot AP-202635, BUD 11/16/2026

Lot AP-202636,........

© The Hill